Inhibition of theophylline metabolism by aciclovir

Biological and Pharmaceutical Bulletin

Volumn 19, Issue 12, 1996, Pages 1591-1595

  Maeda, Yorinobu ^a   Konishi, Toshio ^a   Omoda, Kei ^a   Takeda, Yoshiaki ^a   Fukuhara, Shinji ^a   Fukuzawa, Masataka ^a   Ohune, Terumasa ^a   Tsuya, Takafumi ^a   Tsukiai, Satsuki ^a  

^a CHUGOKU ROSAI HOSPITAL   (Japan)

Author keywords

aciclovir; drug interaction; drug metabolism; metabolic clearance; metabolic inhibition; theophylline

Indexed keywords

ACICLOVIR; DIPROPHYLLINE; THEOPHYLLINE;

ADULT; ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG MONITORING; DRUG OXIDATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; THEOPHYLLINE BLOOD LEVEL;

EID: 0030459395     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.19.1591     Document Type: Article

References (12)

1. May C., Clin. Allergy, 4, 211-219 (1974).
2. Elion G. B., Am. J. Med., 73, 7-13 (1982).
3. Upton R. A., Clin. Pharmacokinet., 20, 66-80 (1991).
4. Kubo H., Nishikawa T., Saito M., Clin. Chem. Symp. (Tokyo), 17, 82-86 (1978).
5. Konishi H., Morita K., Yamaji A., Eur. J. Clin. Pharmacol., 46, 309-312 (1994).
6. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T., J. Pharmacubio-Dyn., 4, 879-885 (1981).
7. Mitenko P., Ogilvie R., N. Engl. J. Med., 289, 600-603 (1973).
8. Ogilve R. I., Clin. Pharmacokinet., 3, 267-293 (1978).
9. Sarkar M. A., Hunt C., Guzelian P. S., Karnes H. T., Drug Metab. Dispos., 20, 31-37 (1992).
10. Antal E. J., Kramer P. A., Mercik S. A., Br. J. Clin. Pharmacol., 12, 637-645 (1981).
11. Takagi K., Hasegawa T., Yamaki K., Suzuki R., Watanabe T., Satake T., Int. J. Clin. Pharmacol. Ther. Toxicol., 26, 288-292 (1988).
12. Sasa M., Naito Y., Jpn. J. Clin. Pharmacol. Ther., 18, 523-536 (1987).